- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01152034
MAPS Group Therapy Model for Bipolar Disorder
Effect of Psychoeducational Group Therapy Model for Bipolar Disorder Patients
This study aims to develop the MAPS(M,Monitoring;A,Assessing;P,Preventing or Reducing Relapse;S,Smart goal setting) group therapy model for bipolar disorder patients as other adjuvant clinical treatment and develop the instruments for evaluating the severity of bipolar symptoms. The investigators insist to provide the psychosocial intervention for bipolar patients in the general hospital and offer appropriative adjuvant intervention except current psychiatric biological treatment.
This study is a one-year project. First, the investigators like to translate the Depression, Anxiety and Stress Scale (DASS) and the Altman Self-Rating Scale for Mania (ASRM) to Chinese and finish the reliability and validity study. Second, the investigators would like to develop the MAPS group therapy to enhance bipolar patients' insight, increased life quality and decrease suicidal ideation. This study is a case control study. All cases recruit from the psychiatric outpatient department of one medical center. The inclusion criteria are diagnosed as bipolar disorder, age from 18 to 65 and agree to sign the inform consent. The excluded criteria are hard to communicate, with acute psychiatric feature and severe physical illness. The investigators plan to hold the MAPS group three times and predetermine to recruit totally 30 patients as the case group. As to the control group, the investigators also recruit from the psychiatric outpatient department and those who treat as usual by control their gender, age and the same diagnosis as bipolar disorder. The only one different factor between the case group and the control group was attending the MAPS group therapy or not. In MAPS group therapy, two facilitators work with ten clients with twelve weekly sessions and three monthly booster sessions. Self-report rating scales (DASS and ASRM) are completed at the beginning of each session. The investigators use DASS and ASRM to evaluate the severity of bipolar symptoms; BSS for suicidal ideation; SF-36 for life quality. The hypothesis is "patients attended to MAPS group therapy have better symptoms control, lower suicidal ideation, better life quality and less use emergency department or admissions than those who didn't attend the group therapy".
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei City, Taiwan
- Mackay Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- bipolar disorder outpatients in remission, defined as Young Mania Rating Scale score < 6, Hamiltone Depression Rating Scale-17 < 8
- age 18 to 65 years old
- speaking Mandarin
- agree to sign the inform consent
Exclusion Criteria:
- Those who were hard to communicate such as mental retardation, hearing impairment and etc
- with acute psychotic feature
- with severe physical illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Psychoeducation group therapy
The structured group program comprised of an initial block of 12 weekly sessions with three additional monthly booster sessions, designed to support participants in the application of knowledge and skills to everyday life situations.
All participants also received standard psychiatric care as well.
|
This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity.
The program will be in groups of 6-12, conducted by two experienced therapists.
The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
|
|
Placebo Comparator: Treat as Usual
Patients who were assigned to the control group received standard psychiatric care and standard pharmacological treatment without group-based psychosocial intervention.
Weekly phone calls to the control group over the initial 12 weeks were controlled for any extra contact time with researchers outside of the structured intervention group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The main outcome measures are time to recurrence a new acute bipolar episode
Time Frame: every 3 months for up to 12 months after enrollment
|
This is defined as the time (days) elapsed between baseline and the emergence of a new acute episode according to DSM-IV criteria and scores above or equal to 20 on the YMRS for manic recurrence; above or equal to 12 for hypomanic recurrence; above or equal to 17 on the HRSD-17 for depressive recurrence; and above or equal to 20 on the YMRS and 12 on the HRSD-17 for mixed recurrence.
|
every 3 months for up to 12 months after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of recurrences
Time Frame: every 3 months for up to 12 months after enrollment
|
The number of recurrences, separating for type of episode (manic, hypomanic, mixed or depressive) will also be recorded as a secondary outcome measure.
|
every 3 months for up to 12 months after enrollment
|
|
Time spent ill
Time Frame: every 3 months for up to 12 months after enrollment
|
Another secondary outcome measure is time spent ill.
The investigators obtain this data by prospectively registering the number of days that a participant fulfilled criteria for a specific episode.
|
every 3 months for up to 12 months after enrollment
|
|
Psychiatric outpatient adherence and drug compliance
Time Frame: every 3 months for up to 12 months after enrollment
|
The medication compliance questionnaire reported compliance with any prescribed mood stablizers.(Lam
DH, et al. 2000, 2005) Respondents had a choice of noting whether the patient in the past month had (1) never missed taking their medication, (2) missed taking it once or twice, (3) missed taking it between three to seven times, (4) missed taking it more than seven times, or (5) stopped taking it altogether.
|
every 3 months for up to 12 months after enrollment
|
|
Numbers and time of emergency use and hospitalization
Time Frame: every 3 months for up to 12 months after enrollment
|
The number of hospitalizations, reasons for admission and total number of days that the participant remained hospitalized will also be recorded during follow-up period.
|
every 3 months for up to 12 months after enrollment
|
|
Suicidal ideation and number of suicidal attempt
Time Frame: every 3 months for up to 12 months after enrollment
|
The Chinese version of Scale for Suicide Ideation had been translated and the excellent psychometric properties for measuring suicidal ideation in Chinese populations were done (Zhang and Brown, 2007).
The BSS and the suicidal attempts will be re-assessed every 3 months or whenever a new episode was suspected by the psychiatrist in charge of the participant.
|
every 3 months for up to 12 months after enrollment
|
|
The life quality of bipolar patients
Time Frame: every 3 months for up to 12 months after enrollment
|
This SF-36 Taiwan standard version was developed in 1996 following the protocol by the International Quality of Life Assessment (IQOLA) Project.
The protocol includes forward and backward translation, focus group discussion, pilot testing, and extensive psychometric analysis of the translation.
(Fuh JL et al, 2000; Chang DF,et al, 2000).The SF-36 Taiwan standard version will be also repeated every 3 months or whenever a new episode was suspected by the psychiatrist in charge of the participant.
|
every 3 months for up to 12 months after enrollment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MMH-I-S-662
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeWithdrawnBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Vielight Inc.Not yet recruitingBipolar Disorder (BD) | Bipolar | Bipolar Disorder DepressionCanada
-
Xenon Pharmaceuticals Inc.RecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Xenon Pharmaceuticals Inc.Enrolling by invitationBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
University of Texas Southwestern Medical CenterThe Texas Child Mental Health Care Consortium (TCMHCC)RecruitingBipolar Disorder Family Members | Bipolar Disorder (BD) | Bipolar Disorder I or II | Screening ToolUnited States
-
University of California, Los AngelesUniversity of Colorado, Denver; University of Pittsburgh; University of Cincinnati and other collaboratorsRecruitingAdolescents | Bipolar Disorder (BD) | Bipolar Disorder I or II | Bipolar Disorder NOS | Bipolar Spectrum DisorderUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
Babes-Bolyai UniversityRecruitingBipolar Disorder (BD)Romania
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
Clinical Trials on psychoeducation group therapy
-
University of ArizonaCompletedSchizophrenia | Schizoaffective Disorder | Major Depression With Psychotic Features | Bipolar Disorder With Psychotic Features | Psychotic Disorder Not Otherwise Specified (NOS)United States
-
Lev-Hasharon Mental Healtlh CenterUnknownBipolar Affective DisorderIsrael
-
St. Joseph's Healthcare HamiltonNot yet recruiting
-
Sunnybrook Health Sciences CentreTerminated
-
Tugba YildirimCompletedPsychological Flexibility | Somatic SymptomTurkey
-
Muğla Sıtkı Koçman UniversityNot yet recruiting
-
Finnish Institute of Occupational HealthCity of Helsinki; Finnish Work Environment Fund; The Social Insurance Institution... and other collaboratorsCompletedEnvironmental Illness | Functional SymptomsFinland
-
Jordi Gol i Gurina FoundationCarlos III Health InstituteUnknown
-
University Medical Centre LjubljanaUniversity of LjubljanaNot yet recruitingAnorexia Nervosa | Eating DisordersSlovenia
-
Ege UniversityCompletedSubstance-Related Disorders | Disease | Substance Use Disorders | Alcohol Use Disorder | Mental Disorders, SevereTurkey